Global Study on Bone Marrow Transplant Market, 2015-2021

<strong>Global</strong> <strong>Study</strong> on Bone Marrow Transplant Market, 2015-2021
segmented into autologous bone marrow transplant and allogeneic bone marrow transplant
segments. On the basis of disease indication, the market is classified into segments viz.
leukemia, lymphoma, myeloma, myelodysplasia, myeloproliferative neoplasms, aplastic
anemia, solid tumors, sickle cell anemia, thalassemia, and others. As per end user, bone
marrow transplant market is segmented into hospitals, multispecialty clinics, and
ambulatory surgical centers (ASC).
Revenue from the global bone marrow transplant market is projected to expand at a steady
CAGR of 3.9% over forecast period 2015–2021 and is expected to be valued at US$10.3 Bn
by the end of 2021. Among other markets globally, the market in Europe is expected to
remain dominant in terms of value and volume throughout the forecast period.
Major factors driving the growth of the global bone marrow transplant market include
increasing the prevalence of blood cancers and anemia, expanding bone marrow transplant
registries, growing investment in logistic services, and increasing survival rate after
treatment. Moreover, factors such as advances in technology, increasing per capita
healthcare expenditure, and improvement in healthcare infrastructure are also expected to
fuel the growth of the global bone marrow transplant market. However, shortage of bone
marrow donors, uncertainty about reimbursement, and the high cost of treatment are the
major factors expected to hamper the growth of the global bone marrow transplant market.
Owing to relatively less involvement of risks, autologous bone marrow transplant procedures
are being adopted at a faster rate. Hence by procedure type, autologous bone marrow
transplant segment accounted for the major proportion of the overall market volume in 2014
and is expected to remain the leading segment in terms of volume during the forecast
period. By disease indication, the leukemia segment is expected to dominate the market,
accounting for 26.5% share of the overall market revenue by 2021 end. Revenue
contribution from the thalassemia segment is projected to expand at the highest CAGR of
8.9% during the forecast period.
Based on regional segmentation, the market in Europe is expected to continue to lead the
global market due to increasing number of bone marrow transplant centers and expansion of
bone marrow registry. The MEA market is expected to witness sluggish growth during the
forecast period partly due to the relatively low presence of bone marrow transplant centers
Persistence Market Research 4